Organogenesis Investor Relations Material

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes advanced wound care and surgical tissue products for the treatment of diabetic foot ulcers and difficult-to-heal wounds. The Company's line of human amniotic membrane allograft and synthetic regenerative skin substitutes offer benefits over traditional wound healing therapies, including lower cost, reduced recovery time and improved patient outcomes. Organogenesis utilizes its proprietary technology to manufacture human amniotic membrane allografts derived from donated tissues collected during childbirth. In addition, Organogenesis markets its synthetic skin substitute called NuriSkinall which can be used as an alternative to real skin in reconstructive procedures such as breast reconstruction and replacement of full thickness burns through treating physicians and hospitals in the United States.